CD274 and non-small cell lung carcinoma: The American Society of Clinical Oncology (ASCO) guidelines12 for stage IV NSCLC without driver alterations strongly recommend single‐agent pembrolizumab as a first‐line treatment for patients with ≥50% expression of programmed death‐ligand 1 (PD‐L1).